‹ ›
MYP_034286
← PREVIOUS NEXT → BACK
Basic Information
Enfuvirtide [S138R], T-20 [S138R]
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Standard
36 amino acids
C205H305N53O63
Standard
Sequence
YTSLIHSLIEERQNQQEKNEQELLELDKWASLWNWF
Physicochemical Analysis
4519.93 Da
4.54
-4.14
-4.41
-0.1149
-0.98
0.46
-0.11
57.30
89.44
0.1389
17990.00
17990.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1935.69
-14.69
65.0
60.0
153.0
321.0
9.0
42.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0149941 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
PaperDesign of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20 PMID19073606 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19073606/
RECORD: Rec_0172647 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1N43D/S138A | HeLa cells
1 μM
EC50
Mammalian: 2.8 h; Yeast: 10 min; E. coli: 2 min
PaperDesign of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. | Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M. | J Biol Chem. 2009 Feb 20;284(8):4914-20. | DOI:10.1074/jbc.M807169200 | PMID:19073606 PMID19073606 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19073606/
RECORD: Rec_0233233 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1N43D | HeLa cells
1 μM
EC50
Mammalian: 2.8 h; Yeast: 10 min; E. coli: 2 min
PaperDesign of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. | Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M. | J Biol Chem. 2009 Feb 20;284(8):4914-20. | DOI:10.1074/jbc.M807169200 | PMID:19073606 PMID19073606 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19073606/
RECORD: Rec_0259119 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1WT | HeLa cells
0.362±0.114 μM
EC50
Mammalian: 2.8 h; Yeast: 10 min; E. coli: 2 min
PaperDesign of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20. | Izumi K, Kodama E, Shimura K, Sakagami Y, Watanabe K, Ito S, Watabe T, Terakawa Y, Nishikawa H, Sarafianos SG, Kitaura K, Oishi S, Fujii N, Matsuoka M. | J Biol Chem. 2009 Feb 20;284(8):4914-20. | DOI:10.1074/jbc.M807169200 | PMID:19073606 PMID19073606 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19073606/
RECORD: Rec_0269294 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HIV-1 NL4-3 N43D
PMID19073606 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/19073606/
FIRST PREV 1 2 3
Showing 5 records on this page · Page 3 of 3